title: Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.
abstract: Many tumours express tumour-specific antigens capable of being presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Current models of antigen presentation predict that the tumour cell itself should present its own MHC class I-restricted antigens to T cells. Earlier cross-priming experiments have demonstrated that at least some MHC class I-restricted antigens may also be presented by bystander cells. There is no detectable presentation of MHC class I-restricted tumour antigens by the tumour itself during priming of tumour-specific responses. The tumour antigens are presented exclusively by host bone marrow-derived cells. These results imply that an efficient mechanism exists in vivo for transfer of MHC I-restricted antigens to bone marrow-derived antigen presenting cells. They also suggest that HLA matching may not be critical in the clinical application of allogeneic tumour vaccines.
authors.affiliation: Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
authors.forename: A Y
authors.initials: AY
authors.lastname: Huang
authors.forename: P
authors.initials: P
authors.lastname: Golumbek
authors.forename: M
authors.initials: M
authors.lastname: Ahmadzadeh
authors.forename: E
authors.initials: E
authors.lastname: Jaffee
authors.forename: D
authors.initials: D
authors.lastname: Pardoll
authors.forename: H
authors.initials: H
authors.lastname: Levitsky
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis*; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D001854:Bone Marrow Cells; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D051379:Mice
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D015395:Histocompatibility Antigens Class I